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Both natural viral infections and therapeutic interventions using viral vectors pose signiﬁcant
risks of malignant transformation. Monitoring for clonal expansion of infected cells is
important for detecting cancer. Here we developed a novel method of tracking clonality via
the detection of transgene integration sites. RAISING (Rapid Ampliﬁcation of Integration Sites
without Interference by Genomic DNA contamination) is a sensitive, inexpensive alternative
to established methods. Its compatibility with Sanger sequencing combined with our CLOVA
(Clonality Value) software is critical for those without access to expensive high throughput
sequencing. We analyzed samples from 688 individuals infected with the retrovirus HTLV-1,
which causes adult T-cell leukemia/lymphoma (ATL) to model our method. We deﬁned a
clonality value identifying ATL patients with 100% sensitivity and 94.8% speciﬁcity, and our
longitudinal analysis also demonstrates the usefulness of ATL risk assessment. Future studies
will conﬁrm the broad applicability of our technology, especially in the emerging gene therapy
sector.
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pproximately 10–15% of all human cancers are associated
with viral infections1. A subset of viruses integrates into
their host genomes, and the integration often causes
malignant transformation by affecting the expression of cancer
driver genes2–4. This phenomenon is also a known complication
of retrovirus-based therapeutics. Indeed, a subset of retroviral
gene therapy-treated patients with X-linked severe combined
immunodeﬁciency developed T-cell acute lymphoblastic leukemia
due to proto-oncogene activation5,6. Although efforts are
underway to limit this problem, it is still impossible to control the
viral vector integration site. Moreover, although genome editing
technologies foregoing the use of viral vectors are expected to
enter the gene therapy arena7, these too have risks associated with
off-target editing and unpredictable integration8,9. Therefore, it is
critical to develop a clinically applicable method of monitoring
integration sites and the clonality of transgene-integrated cells to
detect early signs of cancer.
Several such methods of analyzing transgene integration events
using high thoroughput sequencing (HTS) have recently been
developed: namely, ligation-mediated PCR10,11, target-capture
sequencing12,13, LAM-PCR (linear ampliﬁcation-mediated
PCR)14, nrLAM-PCR (non-restrictive linear ampliﬁcationmediated PCR)15,16, and tag-PCR17. Some of these methods
have already been employed in clinical settings to assess the safety
of retroviral and lentiviral gene therapies14,15. However, HTS
analysis remains prohibitively expensive for the many researchers
and physicians seeking a more practical solution, especially in
countries where such resources are scarce18. In addition, there are
concerns about the poor sensitivity of methods like LAM-PCR or
Target-capture sequencing that utilize restriction enzymes or
sonication to fragment the DNA. Since fragmentation occurs
randomly, only a small fraction of fragments often include
enough transgene to anneal to the primers or capture with probes
and an appropriate length of host genome for further analysis,
which greatly limits the sensitivity of these methods. The newer
nrLAM-PCR method eliminates the restriction digest step, greatly
increasing the copy number of transgene-integrated fragments.
However, this method suffers from the limitations of the singlestranded linker ligation system, namely a very long 32-h run-time
with low efﬁciency15,16.
Previously, we developed a novel method designed to overcome the limitations mentioned above of currently available
integration site analysis technologies. Known as Rapid Ampliﬁcation of Integration Sites (RAIS), our protocol substituted a
polyA-tailing step for the single-stranded linker ligation system,
shortening the run-time from 32 to 4 h and increasing the sensitivity 100-fold19. While RAIS represented a major improvement
over nrLAM-PCR, uptake of the technology was still limited by
the high cost of biotinylated primers and magnetic streptavidin
beads. Another drawback was the requirement for two ssDNA
puriﬁcation steps, which decreased sensitivity. With these issues
in mind, we devised the new method described herein, known as
Rapid Ampliﬁcation of Integration Sites without Interference by
Genomic DNA contamination (RAISING). Forgoing the use of
biotinylated primers and magnetic beads, we invented a novel
procedure using poly-AG-tailing and thermomodulation to yield
short, uniform transgene-integrated fragments for ampliﬁcation.
Thus, we evolved our technology to produce a highly costeffective and sensitive method that is practical for routine clinical
testing and basic science research.
Here we describe the development of RAISING and demonstrate the clinical utility of our technology using the retrovirus
human T-cell leukemia virus type-1 (HTLV-1) as a model20.
HTLV-1 infects at least 5–10 million worldwide, including many
in developing countries21. This virus can trigger aggressive cancer, adult T-cell leukemia/lymphoma (ATL), as well as a
2

debilitating neuroinﬂammatory disease, HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP)22–24. Since
ATL has an extremely high case fatality rate, it is paramount to
detect cancer and begin treatment as early as possible; those at
high risk of developing ATL must be identiﬁed and closely
monitored. Screening for patients with high HTLV-1 proviral
load in the peripheral blood is reportedly useful but certainly not
speciﬁc13,25. However, studies using HTS technology have
revealed a more speciﬁc metric for ATL risk: the oligoclonality
index (OCI), which quantiﬁes the clonality of HTLV-1-infected
cells, combined with the detection of somatic mutations11,13,26.
Here we use RAISING to rapidly analyze more than 700 samples
from HTLV-1-infected patients and deﬁne our metric for ATL
risk assessment, demonstrating the utility of RAISING for clinically applicable integration site analysis.
Results and discussion
Development of RAISING. Here we describe the development of
our novel method, RAISING, comprising six steps to achieve
ampliﬁcation of transgene-integrated fragments within only 3.5 h,
plus an additional step for Sanger sequencing or HTS library
preparation (Fig. 1a, see also protocol for RAISING in Supplementary information).
Step 1: Single-stranded DNA (ssDNA) synthesis. This step is critical for increasing the sensitivity of RAISING by synthesizing the
ssDNA of transgene-integrated fragments using a single
transgene-speciﬁc primer, F1. To determine factors inﬂuencing
the sensitivity, we applied RAISING to two different sources of
genomic DNA as the templates for ssDNA synthesis: freshly
isolated DNA and fragmented DNA with or without RNase A
treatment. As expected, we found that the sensitivity of RAISING
was decreased with the fragmented and RNase A-untreated
genomic DNA (Supplementary Fig. 1a). In addition, we found
that the sensitivity also positively correlated with the amount of
genomic DNA used in this step (Supplementary Fig. 1b). We also
determined that the length of RAISING ﬁnal products depended
on both the quality of genomic DNA and the ssDNA synthetic
time (Supplementary Fig. 1a, c). Although the copy number of
ssDNA can be increased with the cycle number used in the
synthesis (Supplementary Fig. 1d), we decided on 25 cycles to
avoid nonspeciﬁc ampliﬁcation (Supplementary Fig. 1e). We
could detect the appropriate length of ampliﬁed DNA with high
sensitivity using KOD-Plus-Neo (see Fig. 2a) but not OneTaq and
Q5 PCR enzymes (Supplementary Fig. 1f).
Step 2: Column puriﬁcation. Here, we used the Monarch PCR and
DNA cleanup kit to eliminate larger genomic DNA fragments
(>10 kb) as well as the leftover F1 primer while preserving the
ssDNA as well as heat-fragmented smaller genomic DNA
(<10 kb, later referred to as contaminated genomic DNA).
Importantly for extracting ssDNA, this kit requires a low elution
volume with low dead volumes (Supplementary Fig. 2).
Step 3: PolyAG-tailing. The ssDNA and contaminated genomic
DNA isolated in the previous step underwent polyAG-tailing
instead of the polyA-tailing employed in our older RAIS procedure. This is the critical step where the present method diverges
from our previous method. By performing polyAG-tailing in this
step, synthesis of the adaptor primer 1 (ADP1) sequence, a part of
the oligo-dT-adaptor primer 1 (oligo-dT-ADP1) at the 3′-end of
the ssDNA and contaminated genomic DNA, is inhibited in steps
4 and 5. The inhibition sequentially blocks oligo-dT-ADP1mediated ampliﬁcation of contaminated genomic DNA as seen in
amplicons with polyA-tailing (Supplementary Fig. 3a). Thus,
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unlike RAIS, RAISING does not require a biotinylated primer and
magnetic streptavidin beads for eliminating contaminated
genomic DNA.
Step 4: Double-stranded DNA synthesis. In this step, we modulated
the conditions under which oligo-dT anneals to the polyA tails to
produce dsDNA (Supplementary Fig. 3b and Supplementary
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Data 1). In preparation for those using HTS in the ﬁnal step, we
elucidated which oligo-dT-ADP1 produced the most uniform
amplicon lengths. We determined that NV-oligo-dT-ADP1, which
includes VN (V = A or G or C, N = A or G or C or T) at the 3′-end,
performed better than V-oligo-dT-ADP1 (V only) or oligo-dTADP1 (neither V nor N). We also tested the results using Sanger
sequencing and found that in this case, all three produced similar
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Fig. 1 Characterization of Rapid Ampliﬁcation of Integration Site (RAIS) and RAIS without Interference by Genomic DNA contamination (RAISING).
a Schematic representation of RAIS and RAISING. Step 1: Single-stranded DNA (ssDNA) synthesis; Step 2: Column puriﬁcation of ssDNA; Step 3: polyAtailing and polyAG-tailing of ssDNA in RAIS and RAISING, respectively; Step 4: Double-stranded DNA (dsDNA) synthesis; Step 5: DNA puriﬁcation of
dsDNA with magnetic streptavidin-beads in RAIS and ﬁrst PCR in RAISING; Step 6: First PCR in RAIS and second PCR in RAISING; Step 7: Second PCR in
RAIS and Sanger sequencing or high throughput sequencing (HTS) library preparation in RAISING b–d, Linear-ampliﬁcation, accuracy, and consistency
between RAIS and RAISING. Genomic DNA of LMY2 and ED cell lines, each harboring a single HTLV-1 integration site, were mixed at the indicated
percentages, and these mixed samples were processed using both RAIS and RAISING. b Products were visualized by electrophoresis on 2% agarose gels.
c Products were analyzed using Sanger sequencing, with dotted lines indicating the position of the HTLV-1 integration sites. d Products were analyzed using
HTS to measure clone size. Data from two independent experiments (1 and 2) are shown.

Fig. 2 Performance of Rapid Ampliﬁcation of Integration Site without Interference by Genomic DNA contamination (RAISING). All RAISING products
were visualized by electrophoresis on 2% agarose gels. Dotted lines in Sanger sequencing spectra indicate the position of transgene integration sites. a The
sensitivity of RAISING was assessed by serially diluting TL-Om1 genomic DNA (an HTLV-1-infected cell line harboring a single copy of HTLV-1) with Jurkat
genomic DNA (an HTLV-1 negative cell line). Even extremely diluted samples (resulting in PVL as low as 0.032) could be detected by increasing the cycles
in the second PCR of RAISING (left panel). Sanger sequencing analysis of RAISING products conﬁrmed that the same integration site was identiﬁed in
every dilution (right panel). PVL proviral load. b, c Clonality analyses of infected samples using Sanger sequencing (spectra) vs. high throughput
sequencing (HTS, pie charts) showed similar results. b HTLV-1 clonality analysis of an asymptomatic carrier (AC) and an adult T-cell leukemia/lymphoma
(ATL) patient. c Bovine leukemia virus (BLV) clonality analysis of an aleukemic (AL) cow and a cow with enzootic bovine leukosis (EBL). d Successful
ampliﬁcation of various transgene-integrated fragments (HTLV-1; HIV-1 human immunodeﬁciency virus, SIV simian immunodeﬁciency virus, HBV hepatitis
B virus, AdV adenovirus, and low-density lipoprotein receptor knock-in mice Ldlr-mLO-4 and Ldlr-mLO-5) with RAISING. e HBV and AdV integration sites.
f Clonality analysis of HIV-1 and SIV-infected cells with HTS analysis. HTS read counts indicate the size of each clone. g RAISING with HTS analysis was
used to identify on- and off-target effects in Ldlr-mLO-4 and Ldlr-mLO-5 knock-in mice established by genome editing technology. Chr, chromosome.

results, meaning those using Sanger sequencing can choose any of
the three oligo-dT options. Next, we selected a speciﬁc temperature
for the pre-denaturation step to avoid amplifying genomic DNA
contaminants. Without ever heating the reaction to the usual high
temperatures (around 95 °C) used for denaturation, we employed a
5 min 65 °C step followed by an annealing phase using a step-down
4

cycle from 64 to 52 °C. In this way, we could selectively target the
ssDNA produced using the NV-oligo-dT-ADP1 primer without
reaching the temperatures that would denature genomic DNA
contaminants. Finally, to allow steps 3–5 to proceed sequentially in
a single tube, we selected a PCR enzyme that would function efﬁciently among the reagents used in step 3 for polyAG-tailing. The
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Q5 enzyme performed the best under these conditions (Supplementary Fig. 3c). The polyAG-tailing is exchangeable to polyTGtailing if the transgene has a polyA sequence downstream of the
speciﬁc F1 primer (Supplementary Fig. 3d).
Step 5: First PCR. Here, we perform the critical PCR step,
introducing a transgene-speciﬁc F2 primer as the forward primer
and using full-length NV-oligo-dT-ADP1 as the reverse primer. It
should be noted that the ssDNA produced in step 1 is no longer
the template here; because the F2 primer anneals only to the copy
of the transgene produced in the previous step, it can be said that
“template switching” has occurred. Thus, synthesis from the F2
forward primer produces the binding site for the full-length NVoligo-dT-ADP1 reverse primer. Importantly, we designed the
primers to bind at the relatively high annealing temperature of
68 °C; a lower annealing temperature would signiﬁcantly increase
the duration of this step, slowing the overall run-time of our
method. This step, which employs both a forward and a reverse
primer, is essential for ensuring the high speciﬁcity of RAISING.
The method is also highly sensitive due to the unique design
allowing steps 3–5 to proceed uninterrupted in a single PCR tube.
Step 6: Second PCR. We prepared a 1:200 dilution of the ﬁrst PCR
reaction to avoid nonspeciﬁc ampliﬁcation and used two primers
(Sanger-/HTS-F3 and ADP1-HTS-R1) that include half of the
adaptor sequence corresponding to the Illumina high throughput
sequencing (HTS) library. Transgene integration sites can be
analyzed by Sanger sequencing using the amplicons from
this step.
Additional step: HTS library preparation. The amplicons in step 6
can be re-ampliﬁed with two primers that contain 8-nucleotide
sequencing indexes and the remainder of the Illumina adaptor
sequence.
Performance of RAISING. After each RAISING step was fully
evaluated, we compared the performance of RAIS and RAISING
by assessing samples containing different percentages of two
HTLV-1-infected cell lines (ED and LMY2)27,28, each harboring a
single integration site (Fig. 1b–d, and Supplementary Fig. 4a, b).
As expected, the amplicons from RAISING exhibited a superior
(denser) pattern compared to those from RAIS (Fig. 1b). With
both RAIS and RAISING, we observed consistent Sanger
sequence spectra patterns, clone size differing from the expected
result by less than ±10%, and consistent between experimental
replicates within ±2% (Fig. 1c, d). These results clearly indicate
that while both RAIS and RAISING are effective, unbiased
methods, RAISING is better suited to produce the ﬁnal amplicon
length amenable to subsequent HTS analysis.
Each method was tested on samples where genomic DNA from
the HTLV-1-infected cell line TL-Om1 was serially diluted with
genomic DNA from the HTLV-1-negative Jurkat cell line to
compare the sensitivity limits of RAISING and RAIS19. While
RAIS could not be used to amplify integrated fragments in
samples with a proviral load (PVL) <0.16%, the limit for
RAISING was PVL 0.032%, indicating RAISING achieved a
ﬁve-fold higher sensitivity compared to RAIS (Fig. 2a). We also
conﬁrmed the effectiveness of cell-direct RAISING on samples of
HTLV-1-infected cell lines (KK1 and SLB-1) harboring multiple
integration sites (Supplementary Fig. 5a–c).
Consistent with previous results achieved using RAIS19,
RAISING discriminated between non-malignant and malignant
samples in both HTLV-1-infected human specimens and bovine
leukemia virus (BLV)-infected cattle specimens successfully,
regardless of whether Sanger sequencing or HTS was used for
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analysis (Fig. 2b, c, and Supplementary Data 2). By simply
changing the transgene-speciﬁc primer sets, we could use the
same RAISING method to amplify transgene-integrated fragments from a variety of virus-infected and genome-edited
samples (HTLV-1; HIV-1, human immunodeﬁciency virus; SIV,
simian immunodeﬁciency virus; HBV, hepatitis B virus; AdV,
adenovirus; and low-density lipoprotein receptor knock-in mice
Ldlr-mLO-4 and Ldlr-mLO-5) (Fig. 2d). When analyzing
monoclonal expanded cells, we could identify the integration site
using Sanger sequencing (Fig. 2e); for the analysis of polyclonally
expanded cells, we could detect both the integration site and the
size of each clone using HTS analysis (Fig. 2f). Importantly,
RAISING with HTS analysis also successfully discriminated
between on- and off-targets integrating the Loxp donor sequence
into an unpredictable position in the genome-edited Ldlr-knockin mice (Fig. 2g). Collectively, these results demonstrate that
RAISING is a high-performance method for characterizing
multiple-transgene integration events.
Practical application of RAISING-CLOVA in a clinical ﬁeld.
Quantifying the clonality of HTLV-1-infected cells in patients is
essential for assessing their risk of developing aggressive cancer
ATL. In this study, we developed our software, known as CLOVA
(Clonality value), that can automatically provide a clonality value
(Cv) simply by uploading Sanger sequencing data (ab1 ﬁle),
entering the proviral sequence (up to 20 bp adjacent to the host
genome sequence in 5′–3′ orientation), and selecting the desired
nucleotide length for analysis (Supplementary Fig. 6a, b)19.
We demonstrated that visual Sanger sequence spectra could be
converted to a quantitative HTLV-1 clonality value. Theoretically,
the total signal peak area for 20 nucleotides of the HTLV-1
sequence and 20 nucleotides of the host genome sequence should
be identical in a monoclonal sample. In other words, there is a 1:1
ratio between the host genome and HTLV-1 spectral areas, which
we classify as a Cv of 1.00. With polyclonal samples, increasing
the number of clones reduces the intensity of the host genome
signal, and thereby the host genome spectral area, lowering this
ratio and yielding Cv < 1.00 (Supplementary Fig. 6c). Practically,
slight differences in intensity between different nucleotide
sequences exert a minor inﬂuence on the Cv. For example,
occasionally, a sample may yield Cv > 1.00, which should be
interpreted as Cv = 1.00, a monoclonal sample. We also showed
that Cv accurately reﬂected the size of the dominant clone (ﬁrst
clone), as measured using HTS analysis (Supplementary Fig. 7a,
b). We have previously shown that multiclonal expansion of
malignant cells occurs in ~30% of ATL patients19. Therefore, we
incorporated a function into CLOVA that provides nucleotide
sequences for both the ﬁrst and second clones. Subsequently,
these sequences can be searched on BLAST homology to conﬁrm
that two integration sites have been accurately identiﬁed
(Supplementary Fig. 8a, b).
To measure the precision of RAISING-CLOVA, we performed
ﬁve independent analyses on four samples from HTLV-1-infected
subjects with differing Cv values (sample A, 0.88; sample B, 0.57;
sample C, 0.40; sample D, 0.12), and we found the variation in Cv
was less than ±0.03 in all samples (Supplementary Fig. 9).
Similarly, two different laboratories measured the clonality of the
same HTLV-1-infected samples using the RAISING-CLOVA
method with a high interrater agreement (Supplementary Fig. 10,
n = 62). Finally, we tested whether RAISING-CLOVA could be
used to measure clonality when applied directly to whole blood
samples without isolating peripheral blood mononuclear cells
(PBMCs). We tested RAISING-CLOVA on whole blood samples
and PBMCs from the same patients and determined that the
performance was similar (Supplementary Fig. 11, n = 51).
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We began investigating the clinical utility of RAISING-CLOVA
by assessing the suitability of Cv for discriminating between
samples from patients with and without the HTLV-1-associated
cancer ATL. Since HTLV-1 proviral load (PVL) has long been
considered an important marker for the development of ATL25,29,
we directly compared the performance accuracy of Cv and PVL.
We determined the Cv of specimens from asymptomatic carriers
(AC, n = 201), patients with HAM/TSP (n = 223), and ATL
patients (n = 286). Of these 710 subjects, blood samples suitable
for measuring HTLV-1 proviral load (PVL) were available for 688
(Supplementary Data 3). As reported previously, patients with
HAM/TSP and ATL exhibited signiﬁcantly higher PVL than ACs
(Fig. 3a)30,31. Within the ATL group, patients with chronic or
acute subtypes exhibited signiﬁcantly higher PVL than those with
smoldering subtypes (Supplementary Fig. 12a). On the other
hand, Cv in patients with HAM/TSP was as low as that of ACs,
and patients with ATL exhibited signiﬁcantly higher Cv than both
ACs and those with HAM/TSP (Fig. 3b). Within ATL subtypes,
Cv of the smoldering type was signiﬁcantly lower (Supplementary
Fig. 12b), supporting the clonal progression model for ATL that
we proposed previously32. Upon analyzing receiver operating
characteristics (ROC), we determined that Cv analysis was more
effective for discriminating ATL from both AC and HAM/TSP
than PVL analysis (Cv: AUC 0.996, PVL: AUC 0.941,
Supplementary Fig. 13a, b). We also compared our results to
the oligoclonality index (OCI) by Gillet NA et al. 11, another
metric for quantifying HTLV-1 clonality. We found a correlation
between Cv and OCI (Supplementary Fig. 14) and similar
clonality patterns among AC, HAM/TSP, and ATL. These suggest
that Cv from RAISING-CLOVA can be an alternative to OCI.
To assess the diagnostic value of our technology, we proceeded
to deﬁne cut-off values for distinguishing subjects with and
without ATL using Cv and PVL (Fig. 3c). As a preliminary step,
we presupposed that subjects with a PVL <0.5% might be
classiﬁed as non-ATL without measuring Cv. We have conﬁrmed
that RAISING-CLOVA can accurately measure Cv when the PVL
is at least 0.5%, but not lower (Supplementary Fig. 15). Though
this may be considered a technical limitation, it is well established
that ATL risk increases with higher PVL, so it may not be useful
to measure Cv when PVL is below this very low threshold.
Indeed, in our study, we report no ATL patients with PVL <0.5%.
Next, among subjects with a PVL of at least 0.5%, we determined
a Cv cut-off value of 0.48, which could distinguish all subjects
with and without ATL with 100% sensitivity and 94.8%
speciﬁcity. For comparison, PVL ≥ 4% has been previously
proposed as a diagnostic test25, and this cut-off value would
produce only 96.2% sensitivity and 62.3% speciﬁcity.
We then took the ﬁrst steps towards classifying a potential ATL
risk by Cv. We decided that subjects with Cv above the cut-off as
mentioned earlier of 0.48 would be classiﬁed as zone 3 and ATL
zone (Table 1). We conﬁrmed that even non-ATL subjects above
this cut-off possessed a large dominant clone (≥~40% of the total
infected cells), which is highly suggestive of ATL complication as
well as malignant expansion. To ﬁnd a cut-off for classifying the
remaining subjects into the other two zones, we analyzed the
distribution of Cv values among subjects without ATL (Fig. 3d,
n = 364). We employed a common method using the derivative
function with intervals of 0.05 to identify the inﬂection point Cv
0.25. The vast majority (86%) of non-ATL subjects in our study
thus fell into a typical non-ATL category (zone 1), with Cv < 0.25.
In addition, the dominant clone size in this zone was all relatively
small (<~13%), suggesting a low risk of progression to ATL.
Of course, any risk assessment analysis using only crosssectional data should be interpreted with caution, and it is
important to validate our proposed Cv cut-off values in a
longitudinal study. Therefore, we conducted a retrospective
6

longitudinal analysis using available samples from 15 progressors
to ATL and 130 non-progressors (Fig. 4 and Supplementary
Data 4). In this analysis, we assessed the prognostic value of Cv
compared with established markers such as PVL and soluble IL-2
receptor (sIL-2R) (Fig. 4a). ROC analysis was performed using
available data in a time point between one month and one year
before either ATL onset or ﬁnal visit of non-progressors
(progressors to ATL, median 7.0 months ago; non-progressor,
median 6.2 months ago). The results demonstrated that Cv was
the most effective marker to distinguish between progressors and
non-progressors (Fig. 4b, Cv: AUC 0.880, PVL: AUC 0.738, sIL2R: 0.782). We determined Cv 0.50 as a cut-off value that
rendered enough speciﬁcity (≥95%) to identify ATL high-risk AC
and HAM/TSP patients (Table 2). The cut-off values for PVL and
sIL-2R with similar speciﬁcity were 13.5% and 1260 U/mL,
respectively, but their sensitivities were much lower than that of
Cv. Likewise, we determined Cv 0.24 as a cut-off value that
rendered enough sensitivity (≥80%) to identify ATL middle-risk
patients. The cut-off values for PVL and sIL-2R with similar
sensitivity were 5.0% and 479 U/mL, respectively, but their
speciﬁcities were much lower than that of Cv. As a result, the
longitudinal analysis provided quite similar cut-off values as
obtained from cross-sectional data. In this study, we found that
clonal expansion of (pre-) leukemic cells was detectable by
increasing Cv months or even years. Therefore, these suggest that
rising Cv may be an effective early warning sign for clinicians
monitoring these patients. Finally, the dramatic decrease in Cv
after one of the ATL patients was treated suggests that RAISINGCLOVA may also be a useful tool for assessing the effectiveness of
ATL therapeutic agents (Supplementary Fig. 16 and Supplementary Data 4). We used HTS analysis to conﬁrm that the sharp
decrease in Cv did indeed correspond to eradicating the
dominant clone in this patient. Collectively, these results suggest
it may be beneﬁcial to monitor patients with HTLV-1 using
RAISING-CLOVA to detect the earliest signs of progression to
ATL. Once high-risk individuals are identiﬁed, we recommend
supplementing Cv analysis by pursuing mutational proﬁling of
genes mutated in ATL frequently13,26,33.
Thus, we performed a comprehensive HTLV-1 clonality
analysis with RAISING-CLOVA and developed a method for
early detection and risk assessment for progression to ATL
among HTLV-1-infected patients. However, there are several
limitations in this study that should be noted. Firstly, we found
that ~2% of our ATL specimens (n = 5) carried a dominant
clone with a variant of the provirus known to lack the 3’ long
terminal repeat where HTLV-1-speciﬁc F2 and F3 primers
bind12,34. Unsurprisingly, RAISING failed to the HTLV-1integrated fragment of the dominant clone in these cases.
Therefore, it is important to keep this limitation in mind and
use another method such as southern blot analysis or targetcapture sequencing to determine clonality in these patients13,19.
Secondly, regarding the ATL risk assessment method developed
herein, we only used peripheral blood samples of HTLV-1infected individuals, which may only be accurate for predicting
the leukemia subtypes of ATL. For example, in a patient who
developed the lymphoma subtype, we found that the Cv in
peripheral blood (0.23) was much lower than that in the lymph
node (0.94) (Supplementary Fig. 17). Similarly, PVL in the
peripheral blood was only 0.17%, indicating a negligible
migration of malignant cells from the lymph node to the
peripheral blood. Therefore, these results underline the need to
utilize appropriate clinical material for clonality analysis in
HTLV-1-infected individuals, especially those with lymphoma
or skin cancer subtypes of ATL.
In conclusion, we introduced the RAISING method employing
Sanger sequencing as a cost-effective alternative to HTS analysis
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for identifying multiple transgene integration sites. We demonstrated that RAISING is even faster and more sensitive than other
previously published methods, and we also introduced a new
CLOVA software to facilitate the clonality analysis. Here we
focused on HTLV-1 as a model system, showing we could
accurately quantify the clonality of infected samples, laying the
foundation for using this method in routine clinical testing for

ARTICLE

HTLV-1-related cancers. Our success measuring the clonality of
samples infected with not only HTLV-1 but also BLV, HIV-1, and
SIV suggests that RAISING shows promise as a broadly
applicable technology. Future studies should explore the full
breadth of these applications, especially the use of RAISING to
assess the safety and off-target effects of forthcoming gene
therapies.

COMMUNICATIONS BIOLOGY | (2022)5:535 | https://doi.org/10.1038/s42003-022-03467-w | www.nature.com/commsbio

7

ARTICLE

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-022-03467-w

Fig. 3 Clinical utility of clonality analysis using Rapid Ampliﬁcation of Integration Site without Interference by Genomic DNA contamination
(RAISING) and Clonality Value (CLOVA) software. HTLV-1 proviral load (PVL, a) and clonality values (Cv, b) of peripheral blood samples from
asymptomatic carriers (AC, n = 201, black), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP, n = 223, blue), and adult T-cell
leukemia/lymphoma (ATL, n = 264, red) patients. The median PVL and Cv in each group and subtype are shown as horizontal lines. p-value were
calculated using Dunn’s multiple comparisons test. ****p < 0.0001, n.s., not signiﬁcant. c Combinational analysis of PVL and Cv using the same samples as
above. Cv 0.48 indicate proposed cut-off values to differentiate ATL from non-ATL. PVL 0.5% (red line) or greater means that Cv is accurate.
d Frequencies of subjects with ATL (red) and without ATL (blue) per Cv at intervals of 0.05. Dotted lines show proposed cut-off values to classify HTLV-1infected patients into three potential ATL risk zones.

Table. 1 Classiﬁcation of a potential Adult T-cell leukemia/lymphoma (ATL) risk based on clonality value of HTLV-1infected cells.
Zonea

PVL (%)

Cv

∼ First clone
size (%)

Non-ATL (n = 424)
AC (n = 201) (%)

HAM/TSP (n = 223) (%)

1

<0.5b
≥0.5b
≥0.5b
≥0.5b

NA
<0.25
0.25–0.47
≥0.48

<∼13

88.6

84.3

0.0

7.5
4.0

11.7
4.0

0.0
100

2
3 (ATL zone)

∼13⎯40
≥∼40

ATL (n = 264) (%)

Cv clonality value, PVL proviral load, NA not applicable, AC asymptomatic carrier, HAM/TSP HTLV-1-associated myelopathy/tropical spastic paraparesis.
aThis method classiﬁes non-ATL subjects into three zones using samples from peripheral blood.
Zone 1: a typical non-ATL.
Zone 2: a potential progression to ATL.
Zone 3: a potential ATL complication.
bRapid Ampliﬁcation of Integration Site without Interference by Genomic DNA contamination (RAISING)-CLOVA can reliably measure Cv when PVL is at least 0.5%, assuring the accuracy of this
method.

Methods
Collection of human and animal samples. Peripheral blood and biopsies (skin,
lymph nodes, and bone marrow) from asymptomatic carriers, HAM/TSP, and ATL
patients were harvested after obtaining informed consent at Nagasaki University
Hospital, St. Marianna University School of Medicine, Oita University, University
of Miyazaki, and as a collaborative project of the Joint Study on Prognostic Factors
of ATL Development (JSPFAD). Regarding ATL patients in this study, the Shimoyama classiﬁcation was used to diagnose and classify the subtypes35. Of 264
total subjects in Fig. 3, at least 170 subjects conﬁrmed that Southern blotting
analysis was conducted as the conﬁrmatory test13,19. This study was primarily
aimed at measuring HTLV-1 clonality in peripheral blood using our technology,
RAISING. Thus, ATL patients who had or might have a clonal expansion of the
malignant cells only in the other tissues were excluded in this study unless there
were available biopsies. This study was approved by the research ethics committee
of Oita University (198), University of Miyazaki [972(G)], Nagasaki University
(16072504), The University of Tokyo (17-118), St. Marianna University School of
Medicine (1646), and National Institute of Infectious Diseases (1120).
Peripheral blood and lymph nodes were harvested from an aleukemic (Holstein
breed, female, 1 year old) and a leukemic BLV-infected cattle (Holstein breed,
female, 4 years old) at dairy farms in Japan. All experimental procedures were
conducted following approval from the local committee for animal studies of
Hokkaido University (17-0024). Collection of BLV-infected cattle specimens was
approved as a simple general permission procedure for using blood samples for
assays. Verbal informed consent was obtained from all animal owners.

of trans-activating crRNA (tracrRNA), 25 ng/μL of two CRISPR RNAs (crRNAs),
and 50 ng/μL of long single-stranded DNA (lssDNA) were simultaneously
microinjected into the cytoplasm of embryos. After culturing in KSOM medium
(Merck, Darmstadt, Germany) overnight, the embryos dividing into two cells were
transferred into pseudo-pregnant females. The tracrRNA, crRNA, and lssDNA
were synthesized by FASMAC Co., Ltd.
Preparation of genomic DNA. Genomic DNA isolated from PBMCs and biopsies
of human specimens and from the TL-Om1, LMY2, ED, Jurkat, and PM1 cell lines
was puriﬁed using a QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany). At
the St. Marianna University School of Medicine, genomic DNA was extracted from
PBMCs and WBCs using overnight proteinase K digestion followed by phenol/
chloroform extraction. In contrast, genomic DNA of whole blood cells was puriﬁed
using Quick-DNA Miniprep Kit (Zymo Research, Irvine, CA, USA). Genomic DNA
isolated from PBMCs and lymph nodes of cattle specimens was puriﬁed using a
Wizard Genomic DNA Puriﬁcation kit (Promega, Madison, WI, USA). Genomic
DNA isolated from the HSC-F cell line was puriﬁed using a DNeasy Blood & Tissue
Kit (Qiagen, Hilden, Germany). Genomic DNA isolated from the HEK-293 cell line
was puriﬁed using Isogen-LS (Nippon Gene, Tokyo, Japan). Genomic DNA of KK1
and SLB-1 was extracted using NEBNext Single Cell Lysis Module with Thermolabile
Proteinase K and RNase A (New England BioLabs, Ipswich, MA, USA).

In vitro HIV-1 and SIV infection. HIV-1 89.6 was produced by transfection of the
p89.6 plasmid into 293T cells using Lipofectamine 2000 (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) according to the manufacturer’s protocol. The cell culture
supernatant was used to transduce the virus into PM1 cells, and then the infected
cells were harvested at day 7 post-infection. HSC-F cells were infected with SIVmac293 in viral solution at a multiplicity of infection (MOI) of 0.005 plaqueforming units per cell, and the infected cells were harvested at day 6 post-infection.

Proviral load (PVL) analysis. Quantitative polymerase chain reaction (qPCR) for
PVL of HTLV-1 was performed using LC480 (NIPPON Genetics, Tokyo, Japan)
with the following primer sets for HTLV-1: probe, 5′-CCAGTCTACGTGTTTGGAGACTGTGTACA-3′; forward primer, 5′-CCCACTTCCCAGGGTTTGGA-3′;
reverse primer, 5′-GGCCAGTAGGGCGTGA-3′. β-globin was used as an internal
control and ampliﬁed with the following primer sets: probe, 5′-AAGGTGAACGTGGATGAAGTTGGTGG-3′; forward primer, 5′-GTGCACCTGACTCCTGAGGAGA-3′; reverse primer, 5′-CCTTGATACCAACCTGCCCAG3′. At the St. Marianna University School of Medicine, PVL was measured using
qPCR as previously described41, and was standardized using the relative ratio
determined in a previous study42. The qPCR for BLV provirus was performed
using Cycleave PCR Reaction Mix (Takara Bio, Otsu, Japan) and Probe/Primer Mix
for BLV (Takara Bio) with a LightCycler 480 system II (Roche Diagnostics,
Mannheim, Germany). Serial dilution of a BLV positive control (Takara Bio) was
used to generate calibration curves to determine the copy number of the BLV tax
gene. Each DNA sample was tested in duplicate. The concentration of DNA was
estimated by measuring the ultraviolet absorbance at 260 nm using a NanoDrop
8000 spectrophotometer (Thermo Fisher Scientiﬁc). The reported values are the
mean numbers of copies per 50 ng of DNA.

Genome editing. Ldlr-knock-in mice were generated using a genome-editing
technology as previously described40. The mouse embryos at the pronuclear stage
were obtained using in vitro fertilization, and 100 ng/μL of Cas9 mRNA, 50 ng/μL

The cell-direct method. The indicated cell number of KK1 and SLB-1 were suspended in 1 μL of phosphate buffer, and then mixed with 0.5 μL of 10× NEBNext
Cell Lysis Buffer (New England BioLabs), 0.5 μL of RNase A (100 ng/μL, New

Cell culture. The HTLV-1-infected cell lines TL-Om1, LMY2, ED, KK1, and SLB-1;
the HTLV-1-negative acute T-cell leukemia cell line Jurkat (Clone E61: ATCC
TIB152); the CD4+ human T-cell line PM1 (3038, NIH AIDS Reagent Program); and
the cynomolgus macaque T-cell line HSC-F (JCRB1164) were cultured in RPMI 1640
medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/
mL streptomycin at 37 °C in a 5% CO2 atmosphere27,28,36–38. The adenovirus-infected
HEK-293 cell line (JCRB9068) was cultured in Dulbecco’s modiﬁed Eagle medium
supplemented with 10% fetal bovine serum at 37 °C in a 5% CO2 atmosphere39.
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Fig. 4 Longitudinal analysis of progressors to ATL and non-progressors with clonality value (Cv), HTLV-1 proviral load (PVL), and soluble IL-2
receptor (sIL-2R). a Cv (top), PVL (center), and sIL-2R (bottom) of 15 progressors (red) and 130 non-progressors (black). The time point of ATL onset or
last observation visit was set to 0 year 0 month (0Y0M) for progressors or non-progressors, respectively. If multiple data existed in each period of one
year, the arithmetic means were displayed. Of 15 progressors, 10 had only data at one-time point before the onset. Data used for the ROC analysis shown in
b is indicated by dashed rectangles. b ROC analysis using available data from progressors (n = 12) and non-progressors (n = 48) in a time point between
one month and one year (0Y1M–1Y0M) before either ATL onset or last observation visit (progressors, median 7.0 months ago; non-progressor, median
6.2 months ago). AUC area under the curve, CI conﬁdence interval.

Table. 2 Risk assessment of adult T-cell leukemia/lymphoma (ATL) development.

Cut-off valuesa for differentiation between middleand high-risk groups
Sensitivity (%)
Speciﬁcity (%)

Cv

PVL

sIL-2R

0.50

13.5

1260

66.7
95.8

50.0
95.8

33.3
95.6

Cut-off valuesa for differentiation between lowand middle-risk groups
Sensitivity (%)
Speciﬁcity (%)

Cv

PVL

sIL-2R

0.24

5.0

479

83.3
79.2

83.3
43.8

83.3
51.1

Cv clonality value, PVL proviral load, sIL-2R soluble interleukin-2 receptor.
aThe cut-off values were determined by the ROC analysis shown in Fig. 4b.

England BioLabs), 0.5 μL of Thermolabile Proteinase K (New England BioLabs),
and 2.5 μL of distilled water. The mixture was incubated 37 °C for 45 min, then at
55 °C for 10 min. Total 5 μL of the mixture was used for RAISING.
Sanger sequencing analysis. Sanger sequencing was performed using the BigDye
Terminator v3.1 Cycle Sequencing Kit according to the manufacturer’s instructions

(Thermo Fisher Scientiﬁc), and the analysis was performed on a 3730Xl DNA
Analyzer (Thermo Fisher Scientiﬁc).
Development and application of CLOVA. We modiﬁed EditR43 to develop
CLOVA, an R program-based software that automatically enables analysis of the
clonality value (Cv) of transgene-integrated cells, by uploading an “ab.1 ﬁle,” a
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Sanger sequencing ﬁle containing the integration site in the host genome sequence,
and entering a transgene sequence (up to 20 nucleotides) adjacent to the host
genome sequence. The analysis can be performed on a web browser with the R
Shiny package44, but without any cumbersome command-line operations. Methods
to obtain the QC ﬁltering, total peak area before ﬁltering plot, and percent noise
peak in EditR were not modiﬁed in CLOVA. CLOVA can display the Cv values and
averages of signal peak area values of the transgene and host genome sequences on
“Data QA: Signal and noise plot (signal: peak area of a representative nucleotide,
noise: total peak area of the other three nucleotides).” As the Cv values and
averages of signal peak area values depend on the length of the transgene sequence,
the length is alterable in the “bp-length (default value: 20)” of CLOVA corresponding to multiple transgenes. To obtain a stable Cv, we recommend examining
the length of the transgene before performing the clonality analysis as we previously described for the analysis of HTLV-1 clonality19. CLOVA has an additional
function that can output the Sanger sequencing results of the base call (ﬁrst clone)
and second call (second clone) with FASTA format on the “Download FASTA/
CSV” tab using sangerseqR45. Because the complexity of Sanger sequence spectra
patterns and the quality of Sanger sequencing results for the ﬁrst and second clones
depend on the individual clone size, we also recommend adjusting the “threshold
for second call (default value: 85)” for the better discrimination of the two clones.
CLOVA consists of R shiny package (tested by version 1.5.0)44, R sangerseqR
package (tested by version 1.22.0)44, R magrittr package (tested by version 1.5)46, R
dplyr package (tested by version 1.0.2)47, R tidyr package (tested by version
1.1.2.9000)48, and R plotly package (tested by version 4.9.2.1)49.

Code availability
CLOVA is available from the following URL: http://fasmac.co.jp/rais_method_case
(Japanese website) and http://fasmac.co.jp/en/rais (English website).
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